Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.
Katherine G YoungEram Haider McInnesRobert J MasseyAnna R KahkohskaScott J PillaSridharan RaghavenMaggie A StanislawskiDeirdre K TobiasAndrew P McGovernAdem Y DawedAngus G JonesEwan R PearsonRaphael Sonabendnull nullPublished in: medRxiv : the preprint server for health sciences (2023)
This review identifies research that helps understand which clinical and biological factors that are associated with different outcomes for specific type 2 diabetes treatments. This information could help clinical providers and patients make better informed personalized decisions about type 2 diabetes treatments. We focused on two common type 2 diabetes treatments: SGLT2-inhibitors and GLP1-receptor agonists, and three outcomes: blood glucose control, heart disease, and kidney disease. We identified some potential factors that are likely to lessen blood glucose control including lower kidney function for SGLT2-inhibitors and lower insulin secretion for GLP1-receptor agonists. We did not identify clear factors that alter heart and renal disease outcomes for either treatment. Most of the studies had limitations, meaning more research is needed to fully understand the factors that influence treatment outcomes in type 2 diabetes.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- insulin resistance
- cardiovascular disease
- end stage renal disease
- blood pressure
- pulmonary hypertension
- genome wide
- ejection fraction
- dna methylation
- heart failure
- newly diagnosed
- metabolic syndrome
- social media
- peritoneal dialysis
- adipose tissue
- skeletal muscle
- replacement therapy
- combination therapy
- smoking cessation
- patient reported outcomes